English
Back
Open Account
VISEN PHARMA-B
wrote a column ·

One Chart to Understand | Vison Pharma 2025 Annual Performance

The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information. Approval Code: COMU20260313/CN/SM About VISEN Pharmaceuticals (2561.HK) $VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales...
The content of this article is sourced from Vison Pharma's 2025 annual performance announcement and publicly available information as of now. Matters such as product approvals and business plans involve uncertainties, and actual progress may be affected by policy, market, and R&D risks. The framework agreements and strategic cooperation mentioned in the article represent intentions reached by the parties regarding cooperative projects. Future specific business cooperation arrangements will depend on the results of further negotiations and respective approvals or authorizations. Vison Pharma has no obligation to update forward-looking information.
Approval Code: COMU20260313/CN/SM
About VISEN Pharmaceuticals (2561.HK)
$VISEN PHARMA-B (02561.HK)$ An innovative biopharmaceutical company focused on endocrine-related treatment areas, committed to providing more humane innovative therapies that allow endocrine patients to experience better treatment processes and outcomes to achieve their desired quality of life. Putting patient needs first, Vison Pharma is dedicated to delivering products and treatment solutions for endocrine diseases that are either first-in-class or best-in-class. Treatment areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. Vison Pharma continues to gather senior professionals with international backgrounds, as well as cutting-edge technologies and resources globally, while deeply expanding its presence in the Chinese market. Headquartered in Suzhou, it has established offices in Shanghai, Beijing, Hong Kong, and Taipei, implementing a full-chain layout in the field of innovative endocrine drugs from research and development to production and sales, allowing more Chinese endocrine patients to benefit earlier from globally advanced and reliable treatment solutions. On March 21, 2025, Vison Pharma officially listed on the main board of the Hong Kong Exchange.
For more information, please visit the Vison Pharma official website:
www.visenpharma.com
Contact us
info@visenpharma.com
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
9654 Views
Comments
Write a Comment...
1